Community Outcome on Narcotic Antagonists

  • Roger E. Meyer
  • Steven M. Mirin
  • Fred Zackon


As described at the outset of this book, there were two general goals of this research program: (1) a multivariate assessment of blocked and unblocked heroin consumption in order to characterize the nature of opioid reinforcement and (2) an approach to developing and evaluating narcotic antagonist treatment for the individual addict. The focus in previous chapters has emphasized the first goal; in this chapter we will present data on our ambulatory care experiences with narcotic antagonist drugs.


Contingency Contracting Community Outcome Heroin Addiction Opiate Addiction Heroin Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Martin, W. R. The basis and possible utility of the use of opioid antagonists in the ambulatory tréatment of the addict. In: The Addictive States (A. Wikler, ed.). Baltimore: Williams and Wilkins, 1968, pp. 367–376.Google Scholar
  2. 2.
    Wikler, A. Conditioning factors in opiate addiction and relapse. In: Narcotics (D. M. Wilmer, and G. G. Kassebaum, eds.). New York: McGraw-Hill, 1965, pp. 85–100).Google Scholar
  3. 3.
    Kleber, H., Kinsella, J. K., Riordan, C., et al. The use of cyclazocone in treating narcotic addicts in a low-intervention setting. Arch. Gen. Psychiatry 30:37–42, 1974.PubMedCrossRefGoogle Scholar
  4. 4.
    Fink, M., Zaks, A., et al. Naloxone in heroin dependence. Clin. Pharmacol. Ther. 9:568–577, 1968.PubMedGoogle Scholar
  5. 5.
    Martin, W. R., Jasinski, D. R., Mansky, P. A. Naltrexone: An antagonist for the treatment of heroin dependence. Arch. Gen. Psychiatry 28:784–791, 1973.PubMedCrossRefGoogle Scholar
  6. 6.
    Braude, M. C., and Morrison, J. M. Pre clinical toxicity studies of naltrexone. In: Narcotic Antagonists: Naltrexone Progress Report (D. Julius, and P. Renault, eds.). NIDA Monograph Series #9, DHEW ADM 76–387, 1976, pp. 16–26.Google Scholar
  7. 7.
    Julius, D., and Renault, P. (eds.). Narcotic Antagonists: Naltrexone Progress Report. NIDA Monograph Series #9, DHEW ADM 76–387, 1976.Google Scholar
  8. 8.
    Hollister, L. E. Philosophy and status of NAS-CENA study. In: Narcotic Antagonists: Naltrexone Progress Report (D. Julius and P. Renault, eds.). NIDA Monograph Series #9 DHEW ADM 76–387, 1976, pp. 45–47.Google Scholar
  9. 9.
    Goldstein, A. Naltrexone in the management of heroin addiction: Critique of the rationale. In: Narcotic Antagonists: Naltrexone Progress Report (D. Julius and P. Renault, eds.). NIDA Monograph Series #9 DHEW ADM 76–387, 1976, pp. 158–161.Google Scholar
  10. 10.
    Rawlins, M., Randall, M., Meyer, R. E., et al. Aftercare on narcotic antagonists: Prospects and problems. Int. J. Addict. 11(3):501–511, 1976.PubMedGoogle Scholar
  11. 11.
    Endicott, J., and Spitzer, R. L. Current and past psychopathology scales: Rationale, reliability and validity. Arch. Gen. Psychiatry 27:678–687, 1972.PubMedCrossRefGoogle Scholar
  12. 12.
    Kleber, H. Clinical experiences with narcotic antagonists. In: Opiate Addiction: Origins and Treatment (S. Fisher, and A. M. Freedman, eds.). Washington, D.C.: Winston, 1974, pp. 211–222.Google Scholar
  13. 13.
    Goldstein, A. Heroin addiction. Sequential treatment employing pharmacological supports. Arch. Gen. Psychiatry 33:353–358, 1976.PubMedCrossRefGoogle Scholar
  14. 14.
    Vaillaint, G. E. A 12 year follow-up of New York narcotic addicts, IV. Some determinants and characteristics of abstinence. Am. J. Psychiatry 123:573–584, 1966.Google Scholar
  15. 15.
    Gibbons, R. J., and Armstrong, J. D. Effects of clinical treatment on behavior of alcoholic patients. Q.J. Stud. Alcohol 18:429–435, 1957.Google Scholar

Copyright information

© Plenum Publishing Corporation 1979

Authors and Affiliations

  • Roger E. Meyer
  • Steven M. Mirin
  • Fred Zackon

There are no affiliations available

Personalised recommendations